MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.660
-0.050
-1.35%
Closed 16:00 09/24 EDT
OPEN
3.800
PREV CLOSE
3.710
HIGH
3.800
LOW
3.632
VOLUME
41.43K
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
1.443
MARKET CAP
99.59M
P/E (TTM)
-8.2619
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
MediWound (MDWD) Investor Presentation - Slideshow
The following slide deck was published by MediWound Ltd. in conjunction with this event.
Seekingalpha · 09/17 18:32
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Administration (FDA) has
GlobeNewswire · 09/16 12:30
Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels
So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have ticked higher again. But as uncertainty regarding another rescue program and the presidential election continues to linger, where does the market go from here? Weighing in for Oppenheimer, Chief
TipRanks · 09/15 17:14
MediWound: An Underfollowed Opportunity At A Discount
MediWound has popped up on my scanner multiple times over the past few years but the conditions never lined up for me to establish a position.Now, I am looking to establish a speculative position ahead of a potential PDUFA for NexoBrid in anticipation the market will start to recognize MDWD's potential.MDWD appears to be an underfollowed ticker that is currently trading at a discount compared to its peers despite having some promising long-term prospects.I discuss some of my leading downside risks and reveal my plan to establish a small position in the coming days or weeks.
Seekingalpha · 09/08 16:16
MediWound to Present at Upcoming Investor Conferences in September
YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Officer
GlobeNewswire · 09/03 14:00
MediWound completes first NexoBrid delivery for $16.5M
Seeking Alpha - Article · 08/25 12:53
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary
GlobeNewswire · 08/25 12:00
MediWound And Vericel Announce Acceptance Of First Delivery Of NexoBrid To BARDA For Emergency Response Preparedness
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ:VCEL) today announced that the Biomedical Advanced Research
Benzinga · 08/25 11:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDWD. Analyze the recent business situations of Mediwound through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDWD stock price target is 7.08 with a high estimate of 10.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 4.95M
% Owned: 18.18%
Shares Outstanding: 27.21M
TypeInstitutionsShares
Increased
7
374.18K
New
6
100.43K
Decreased
3
2.15M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Stephen Wills
Chairman/Executive Director
stephen Wills
Chief Executive Officer
Sharon Malka
Chief Executive Officer
Cal Cohen
Chief Financial Officer
Boaz Gur-Lavie
Executive Vice President/General Counsel/Secretary
Yaron Meyer
Chief Technology Officer
Lior Rosenberg
Other
Ety Klinger
Director
David Fox
Director
Ofer Gonen
Director
Samuel Moed
Director
Assaf Segal
Independent Director
Vickie Driver
Independent Director
Sharon Kochan
Independent Director
Nissim Mashiach
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MDWD
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.